Innovating Works

ICON Clinical Research GmbH

Desconocido
HIPGEN: Placenta expanded adherent stromal cells PLX PAD as an innovative therapy for improving recovery a... ICON CLINICAL RESEARCH GMBH participó en un H2020: H2020-SC1-2016-2017 Aim of the HIPGEN project is to develop the first cell therapy to improve functional recovery following hip fracture arthroplasty. Hip fract...
2017-11-21 - 2022-09-30 | Financiado
PACE: A multicenter phase IIb study using HLA unmatched allogeneic placenta derived stromal cells PLX PAD... ICON CLINICAL RESEARCH GMBH participó en un H2020: H2020-SC1-2016-2017 PACE aims to transform the treatment of patients suffering from critical limb ischemia (CLI), a disease with high medical need, because of l...
2016-12-01 - 2021-12-31 | Financiado
MIROCALS: Efficacy and safety of low dose IL 2 ld IL 2 as a Treg enhancer for anti neuroinflammatory therapy... ICON CLINICAL RESEARCH GMBH participó en un H2020: H2020-PHC-2014-2015 Amyotrophic Lateral Sclerosis (ALS) is a fatal degenerative disorder of the brain and spinal cord affecting some 40,000 individuals in Europ...
2015-04-07 - 2021-09-30 | Financiado
* Datos extraídos de la documentos o webs disponibles en diferentes organismos públicos.